OTS have already identified a number of cancer-specific-genes that would be applicable for development of molecular-targeted anti-cancer therapies. OTS has been pursuing the medicinal discovery research with understanding the subcellular localization, mode of function, and immunogenicity of the target cancer-specific-genes.
- Investor Relations18/01/2017Poster presentation at 2017 Gastrointestinal Cancers Symposium (ASCO GI) on Phase 1 Clinical Study of OTS103/104 (OCV-C02) for colorectal cancer
- Business News15/12/2016Presentation Material of R&D Meeting 2016 (in Japanese)
- Investor Relations06/12/2016Announcement of milestone payment for the progress of Phase III clinical trial of the cancer-specific peptide vaccine S-588410
Our service offers comprehensive analysis of TCR repertoire from blood and tissue samples using next generation sequencing technology. A detailed data analysis will be performed. We ensure that we will perform this service consistently, from sample preparation to delivering results.
and Safer Cancer Treatments
Pursuing “To develop anti-cancer medicine and anti-cancer therapy with high efficacy and minimum risk of adverse events, and to win the war against cancer”, OTS has been conducting research and development, by collaborating with Professor Yusuke Nakamura, a genomics pioneer.